Cardioprotective Effects of LCZ696 (Sacubitril/Valsartan) After Experimental Acute Myocardial Infarction
LCZ696 (sacubitril/valsartan) can lower the risk of cardiovascular events in chronic heart failure. However, it is unclear whether LCZ696 can improve prognosis in patients with acute myocardial infarction (MI). The present study shows that LCZ696 can prevent cardiac rupture after MI, probably due to...
| Main Authors: | , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2017-12-01
|
| Series: | JACC: Basic to Translational Science |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2452302X17302218 |
| _version_ | 1818561645269483520 |
|---|---|
| author | Masanobu Ishii, MD Koichi Kaikita, MD, PhD Koji Sato, MD, PhD Daisuke Sueta, MD, PhD Koichiro Fujisue, MD, PhD Yuichiro Arima, MD, PhD Yu Oimatsu, MD Tatsuro Mitsuse, MD Yoshiro Onoue, MD, PhD Satoshi Araki, MD, PhD Megumi Yamamuro, MD, PhD Taishi Nakamura, MD, PhD Yasuhiro Izumiya, MD, PhD Eiichiro Yamamoto, MD, PhD Sunao Kojima, MD, PhD Shokei Kim-Mitsuyama, MD, PhD Hisao Ogawa, MD, PhD Kenichi Tsujita, MD, PhD |
| author_facet | Masanobu Ishii, MD Koichi Kaikita, MD, PhD Koji Sato, MD, PhD Daisuke Sueta, MD, PhD Koichiro Fujisue, MD, PhD Yuichiro Arima, MD, PhD Yu Oimatsu, MD Tatsuro Mitsuse, MD Yoshiro Onoue, MD, PhD Satoshi Araki, MD, PhD Megumi Yamamuro, MD, PhD Taishi Nakamura, MD, PhD Yasuhiro Izumiya, MD, PhD Eiichiro Yamamoto, MD, PhD Sunao Kojima, MD, PhD Shokei Kim-Mitsuyama, MD, PhD Hisao Ogawa, MD, PhD Kenichi Tsujita, MD, PhD |
| author_sort | Masanobu Ishii, MD |
| collection | DOAJ |
| description | LCZ696 (sacubitril/valsartan) can lower the risk of cardiovascular events in chronic heart failure. However, it is unclear whether LCZ696 can improve prognosis in patients with acute myocardial infarction (MI). The present study shows that LCZ696 can prevent cardiac rupture after MI, probably due to the suppression of pro-inflammatory cytokines, matrix metalloproteinase-9 activity and aldosterone production, and enhancement of natriuretic peptides in mice. These findings suggest the mechanistic insight of cardioprotective effects of LCZ696 against acute MI, resulting in the belief that LCZ696 might be useful clinically to improve survival after acute MI. |
| first_indexed | 2024-12-14T00:53:33Z |
| format | Article |
| id | doaj.art-1edc02772fc24f2193e23944ec9b0e9d |
| institution | Directory Open Access Journal |
| issn | 2452-302X |
| language | English |
| last_indexed | 2024-12-14T00:53:33Z |
| publishDate | 2017-12-01 |
| publisher | Elsevier |
| record_format | Article |
| series | JACC: Basic to Translational Science |
| spelling | doaj.art-1edc02772fc24f2193e23944ec9b0e9d2022-12-21T23:23:41ZengElsevierJACC: Basic to Translational Science2452-302X2017-12-012665566810.1016/j.jacbts.2017.08.001Cardioprotective Effects of LCZ696 (Sacubitril/Valsartan) After Experimental Acute Myocardial InfarctionMasanobu Ishii, MD0Koichi Kaikita, MD, PhD1Koji Sato, MD, PhD2Daisuke Sueta, MD, PhD3Koichiro Fujisue, MD, PhD4Yuichiro Arima, MD, PhD5Yu Oimatsu, MD6Tatsuro Mitsuse, MD7Yoshiro Onoue, MD, PhD8Satoshi Araki, MD, PhD9Megumi Yamamuro, MD, PhD10Taishi Nakamura, MD, PhD11Yasuhiro Izumiya, MD, PhD12Eiichiro Yamamoto, MD, PhD13Sunao Kojima, MD, PhD14Shokei Kim-Mitsuyama, MD, PhD15Hisao Ogawa, MD, PhD16Kenichi Tsujita, MD, PhD17Department of Cardiovascular Medicine, Graduate School of Medical Sciences, Kumamoto University, Kumamoto, JapanDepartment of Cardiovascular Medicine, Graduate School of Medical Sciences, Kumamoto University, Kumamoto, JapanDepartment of Cardiovascular Medicine, Graduate School of Medical Sciences, Kumamoto University, Kumamoto, JapanDepartment of Cardiovascular Medicine, Graduate School of Medical Sciences, Kumamoto University, Kumamoto, JapanDepartment of Cardiovascular Medicine, Graduate School of Medical Sciences, Kumamoto University, Kumamoto, JapanDepartment of Cardiovascular Medicine, Graduate School of Medical Sciences, Kumamoto University, Kumamoto, JapanDepartment of Cardiovascular Medicine, Graduate School of Medical Sciences, Kumamoto University, Kumamoto, JapanDepartment of Cardiovascular Medicine, Graduate School of Medical Sciences, Kumamoto University, Kumamoto, JapanDepartment of Cardiovascular Medicine, Graduate School of Medical Sciences, Kumamoto University, Kumamoto, JapanDepartment of Cardiovascular Medicine, Graduate School of Medical Sciences, Kumamoto University, Kumamoto, JapanDepartment of Cardiovascular Medicine, Graduate School of Medical Sciences, Kumamoto University, Kumamoto, JapanDepartment of Cardiovascular Medicine, Graduate School of Medical Sciences, Kumamoto University, Kumamoto, JapanDepartment of Cardiovascular Medicine, Graduate School of Medical Sciences, Kumamoto University, Kumamoto, JapanDepartment of Cardiovascular Medicine, Graduate School of Medical Sciences, Kumamoto University, Kumamoto, JapanDepartment of Cardiovascular Medicine, Graduate School of Medical Sciences, Kumamoto University, Kumamoto, JapanDepartment of Pharmacology and Molecular Therapeutics, Kumamoto University, Kumamoto, JapanDepartment of Cardiovascular Medicine, National Cerebral and Cardiovascular Center, Osaka, JapanDepartment of Cardiovascular Medicine, Graduate School of Medical Sciences, Kumamoto University, Kumamoto, JapanLCZ696 (sacubitril/valsartan) can lower the risk of cardiovascular events in chronic heart failure. However, it is unclear whether LCZ696 can improve prognosis in patients with acute myocardial infarction (MI). The present study shows that LCZ696 can prevent cardiac rupture after MI, probably due to the suppression of pro-inflammatory cytokines, matrix metalloproteinase-9 activity and aldosterone production, and enhancement of natriuretic peptides in mice. These findings suggest the mechanistic insight of cardioprotective effects of LCZ696 against acute MI, resulting in the belief that LCZ696 might be useful clinically to improve survival after acute MI.http://www.sciencedirect.com/science/article/pii/S2452302X17302218myocardial infarctionnatriuretic peptiderenin-angiotensin-aldosterone |
| spellingShingle | Masanobu Ishii, MD Koichi Kaikita, MD, PhD Koji Sato, MD, PhD Daisuke Sueta, MD, PhD Koichiro Fujisue, MD, PhD Yuichiro Arima, MD, PhD Yu Oimatsu, MD Tatsuro Mitsuse, MD Yoshiro Onoue, MD, PhD Satoshi Araki, MD, PhD Megumi Yamamuro, MD, PhD Taishi Nakamura, MD, PhD Yasuhiro Izumiya, MD, PhD Eiichiro Yamamoto, MD, PhD Sunao Kojima, MD, PhD Shokei Kim-Mitsuyama, MD, PhD Hisao Ogawa, MD, PhD Kenichi Tsujita, MD, PhD Cardioprotective Effects of LCZ696 (Sacubitril/Valsartan) After Experimental Acute Myocardial Infarction JACC: Basic to Translational Science myocardial infarction natriuretic peptide renin-angiotensin-aldosterone |
| title | Cardioprotective Effects of LCZ696 (Sacubitril/Valsartan) After Experimental Acute Myocardial Infarction |
| title_full | Cardioprotective Effects of LCZ696 (Sacubitril/Valsartan) After Experimental Acute Myocardial Infarction |
| title_fullStr | Cardioprotective Effects of LCZ696 (Sacubitril/Valsartan) After Experimental Acute Myocardial Infarction |
| title_full_unstemmed | Cardioprotective Effects of LCZ696 (Sacubitril/Valsartan) After Experimental Acute Myocardial Infarction |
| title_short | Cardioprotective Effects of LCZ696 (Sacubitril/Valsartan) After Experimental Acute Myocardial Infarction |
| title_sort | cardioprotective effects of lcz696 sacubitril valsartan after experimental acute myocardial infarction |
| topic | myocardial infarction natriuretic peptide renin-angiotensin-aldosterone |
| url | http://www.sciencedirect.com/science/article/pii/S2452302X17302218 |
| work_keys_str_mv | AT masanobuishiimd cardioprotectiveeffectsoflcz696sacubitrilvalsartanafterexperimentalacutemyocardialinfarction AT koichikaikitamdphd cardioprotectiveeffectsoflcz696sacubitrilvalsartanafterexperimentalacutemyocardialinfarction AT kojisatomdphd cardioprotectiveeffectsoflcz696sacubitrilvalsartanafterexperimentalacutemyocardialinfarction AT daisukesuetamdphd cardioprotectiveeffectsoflcz696sacubitrilvalsartanafterexperimentalacutemyocardialinfarction AT koichirofujisuemdphd cardioprotectiveeffectsoflcz696sacubitrilvalsartanafterexperimentalacutemyocardialinfarction AT yuichiroarimamdphd cardioprotectiveeffectsoflcz696sacubitrilvalsartanafterexperimentalacutemyocardialinfarction AT yuoimatsumd cardioprotectiveeffectsoflcz696sacubitrilvalsartanafterexperimentalacutemyocardialinfarction AT tatsuromitsusemd cardioprotectiveeffectsoflcz696sacubitrilvalsartanafterexperimentalacutemyocardialinfarction AT yoshiroonouemdphd cardioprotectiveeffectsoflcz696sacubitrilvalsartanafterexperimentalacutemyocardialinfarction AT satoshiarakimdphd cardioprotectiveeffectsoflcz696sacubitrilvalsartanafterexperimentalacutemyocardialinfarction AT megumiyamamuromdphd cardioprotectiveeffectsoflcz696sacubitrilvalsartanafterexperimentalacutemyocardialinfarction AT taishinakamuramdphd cardioprotectiveeffectsoflcz696sacubitrilvalsartanafterexperimentalacutemyocardialinfarction AT yasuhiroizumiyamdphd cardioprotectiveeffectsoflcz696sacubitrilvalsartanafterexperimentalacutemyocardialinfarction AT eiichiroyamamotomdphd cardioprotectiveeffectsoflcz696sacubitrilvalsartanafterexperimentalacutemyocardialinfarction AT sunaokojimamdphd cardioprotectiveeffectsoflcz696sacubitrilvalsartanafterexperimentalacutemyocardialinfarction AT shokeikimmitsuyamamdphd cardioprotectiveeffectsoflcz696sacubitrilvalsartanafterexperimentalacutemyocardialinfarction AT hisaoogawamdphd cardioprotectiveeffectsoflcz696sacubitrilvalsartanafterexperimentalacutemyocardialinfarction AT kenichitsujitamdphd cardioprotectiveeffectsoflcz696sacubitrilvalsartanafterexperimentalacutemyocardialinfarction |